Phase 1 test of a CD19/CD20 therapy for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to sign consent for the study.
- Your lymphoma is a type of B-cell non-Hodgkin lymphoma that is CD19- and CD20-positive (at least 5% on a recent biopsy test).
- Your disease is active even after at least 2 rounds of chemo, and you’ve already had rituximab or another anti-CD20 antibody.
- You have measurable lymphoma (tumors/lesions are big enough, or bone marrow involvement is confirmed) based on records within the last 8 weeks.
- Your recent testing shows no current spread to the brain/spinal fluid, based on MRI plus spinal fluid tests (cytology/flow).
- You can attend visits and get a central line placed; you also must meet basic blood counts and organ function requirements and avoid pregnancy during treatment and for months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
Hear when a new Non Hodgkin's Lymphoma Refractory/Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.